• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.38 +0.45 (+0.93%)
Streaming Delayed Price Updated: 10:19 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,468,804
Open 49.30
Bid (Size) 49.38 (300)
Ask (Size) 49.39 (400)
Prev. Close 48.93
Today's Range 49.30 - 49.84
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 2.37%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗
Today 6:52 EST
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally. 
Via The Motley Fool
Topics Intellectual Property
News headline image
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗
February 12, 2026
The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts. 
Via Stocktwits

Performance

YTD
-5.7%
-5.7%
1 Month
-17.2%
-17.2%
3 Month
+0.5%
+0.5%
6 Month
-3.1%
-3.1%
1 Year
-39.6%
-39.6%

More News

Read More
News headline image
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗
February 12, 2026
Via The Motley Fool
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
February 12, 2026
Via Stocktwits
News headline image
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs ↗
February 12, 2026
Via Benzinga
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗
February 11, 2026
Via Stocktwits
News headline image
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗
February 11, 2026
Via Stocktwits
Topics Intellectual Property
News headline image
The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty
February 11, 2026
Via MarketMinute
Topics Bonds Economy Government
News headline image
Disney Has Its Next CEO ↗
February 11, 2026
Via The Motley Fool
News headline image
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗
February 11, 2026
Via The Motley Fool
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
February 11, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
February 11, 2026
Via The Motley Fool
News headline image
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
February 10, 2026
Via The Motley Fool
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
February 10, 2026
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
February 10, 2026
Via Stocktwits
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
February 10, 2026
Via The Motley Fool
News headline image
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗
February 09, 2026
Via The Motley Fool
Topics Artificial Intelligence Lawsuit Stocks
News headline image
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗
February 09, 2026
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗
February 09, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Novo Nordisk Stock Just Popped ↗
February 09, 2026
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Why Hims & Hers Stock Just Got Destroyed ↗
February 09, 2026
Via The Motley Fool
Topics Lawsuit
News headline image
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash
February 09, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗
February 09, 2026
Via Stocktwits
Topics Lawsuit
News headline image
Why Eli Lilly Stock Just Popped ↗
February 09, 2026
Via The Motley Fool
Topics Lawsuit
News headline image
The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn
February 09, 2026
Via MarketMinute
Topics Earnings Intellectual Property

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.38
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 02/13/26 10:19 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap